Company Overview and News

 
KLCI expected to start fourth quarter on a subdued note

2018-09-30 theedgemarkets
KUALA LUMPUR (Oct 1): The FBM KLCI is expected to commence the final quarter of 2018 on a subdued note today as market participants await more directions from finance minister Lim Guan Eng when he tables Budget 2019 on Nov 2.
4634 5843 2127 7158 0083 5184 5268 8583 5256

 
Notion VTec, IRIS, Sapura Energy, Mah Sing, Scomi, Pos Malaysia, Reach Energy, Cypark, Comfort Gloves, Gamuda, KPS, Berjaya Corp, MyEG and Ikhmas Jaya

2018-09-28 theedgemarkets
KUALA LUMPUR (Sept 28): Based on corporate announcements and news flow today, companies in focus on Monday (Oct 1) may include: Notion VTec Bhd, IRIS Corp Bhd, Sapura Energy Bhd, Mah Sing Group Bhd, Scomi Group Bhd, Pos Malaysia Bhd, Reach Energy Bhd, Cypark Resources Bhd, Comfort Gloves Bhd, Gamuda Bhd, Kumpulan Perangsang Selangor Bhd (KPS), Berjaya Corp Bhd (BCorp), My EG Services Bhd (MyEG) and Ikhmas Jaya Group Bhd.
4634 5843 2127 7158 0083 5184 5268 8583 5256

 
KLCI slips below 1,800 level as sellers outpace buyers

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI slipped back to below the 1,800-point level at midday break today, as sellers overtook buyers at the local bourse.
HLFBF 7113 7158 BATS TPGVF 4162 2089 5199 5347 7668 TNABY AXXTF 2836 HIPEF 1929 UPBMF 1082 6399 1163 5202 8311 2593 TGLVY 5139 0900 6888 TNABF 3719

 
KLCI erases earlier loss, crosses 1,800-level

2018-09-27 theedgemarkets
KUALA LUMPUR (Sept 27): The FBM KLCI erased its earlier losses and rose at mid-morning to cross the 1,800-point level.
5072 8621 7158 BATS 4162 7215 2089 5199 5347 3301 7668 TNABY AXXTF HIPEF PNAGF UPBMF 1163 5202 8311 6033 2593 5139 PNADF 0900 6888 TNABF 3719

 
The Week Ahead: Keeping an eye on Mahathir’s China trip and July inflation

2018-08-20 theedgemarkets
The spotlight this week will be firmly on the outcome of Prime Minister Tun Dr Mahathir Mohamad’s first official visit to China from Aug 17 to 21.
0104 7889 7158 BSMAF 5168 7045 HRGHY 1818

 
Scomi active, falls 5.26% on capital reduction plan

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): Shares in loss-making Scomi Group Bhd fell 5.26% in active trade this morning after it had proposed a capital reduction of RM440 million to wipe out the ballooning accumulated losses on its balance sheet.
7158

7
Trading ideas: AirAsia, KLK, HSL, Pasdec, Scomi Group, Tan Chong

2018-08-15 thestar.com.my
KUALA LUMPUR: AirAsia Bhd , Kuala Lumpur Kepong Bhd , Hock Seng Lee Bhd (HSL), Pasdec Holdings Bhd , Scomi Group Bhd and Tan Chong Motor Holdings Bhd are among the stocks to watch, according to JF Apex Research.
6912 KLKBY 2445 EXPE 6238 4405 7158

 
KLCI seen rising amid global relief rally, support at 1,773

2018-08-15 theedgemarkets
KUALA LUMPUR (Aug 15): The FBM KLCI is seen rising amid some overnight relief rally at most global markets, immediate support at 1,773.
7158 DKSHY 6912 KLKBY 2445 4995 5225 6238 4405 1899 Q0F IHHHF 5908 DKSHF

7
AirAsia, Batu Kawan, KLK, DKSH, Hock Seng Lee, IHH, Nestlé, Pasdec, Scomi, Tan Chong, Versatile Creative and YTL REIT

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): Based on corporate announcements and news flow today, stocks in focus tomorrow may include: AirAsia Group Bhd, Batu Kawan Bhd, Kuala Lumpur Kepong Bhd, DKSH Holdings (M) Bhd, Hock Seng Lee Bhd, IHH Healthcare Bhd, Nestlé (Malaysia) Bhd, Pasdec Holdings Bhd, Scomi Group Bhd, Tan Chong Motor Holdings Bhd, Versatile Creative Bhd and YTL YTL Hospitality REIT.
SLLXF 7158 532843 DKSHY 6912 KLKBY 2445 4995 EXPE 5225 FORTIS 6238 5109 4405 1899 Q0F IHHHF 5908 DKSHF

 
Scomi proposes RM440 mil capital reduction to offset accumulated losses

2018-08-14 theedgemarkets
KUALA LUMPUR (Aug 14): Loss-making Scomi Group Bhd, whose share price is trading at a record low of 9.5 sen, has proposed a capital reduction of RM440 million to wipe out the ballooning accumulated losses on its balance sheet.
7158 BSMAF 1818

1
KLCI seen drifting lower, immediate support at 1,760

2018-08-02 theedgemarkets
KUALA LUMPUR (Aug 3): The FBM KLCI is seen drifting lower Friday tracking the overnight losses at mot global markets on worries of an escalation in the trade dispute between the U.S. and China, with immediate support at 1,760.
0176 7173 AAPL 7158

 
F&N, Omesti, Toyo Ink, Kronologi Asia, Scomi Group and Unisem

2018-08-02 theedgemarkets
KUALA LUMPUR (Aug 2): Based on corporate announcements and news flow today, companies in focus on Friday (Aug 3) may include: Fraser & Neave Holdings Bhd (F&N), Omesti Bhd, Toyo Ink Group Bhd, Kronologi Asia Bhd, Scomi Group Bhd and Unisem (M) Bhd.
0176 7173 7366 7158 7045

 
Scomi active, falls 9.52% after auditors cast doubt on ability to continue as going concern

2018-08-01 theedgemarkets
KUALA LUMPUR (Aug 1): Scomi Group Bhd shares fell 9.52% in active trade this morning after its independent auditors highlighted a material uncertainty related to the going concern of the group, in an emphasis of a matter paragraph of the audit report for the group's financial year ended March 31, 2018 (FY18).
7158

 
KLCI seen starting off August on a positive note, support at 1,770-level

2018-07-31 theedgemarkets
KUALA LUMPUR (Aug 1): The FBM KLCI is seen starting off August on a positive note today, in line with the overnight gains at most global markets, with support at the 1,770-point level.
5436 5216 0035 7158 5151 7022 GBTKF

 
Scomi Group, YTL Hospitality REIT, Serba Dinamik, Perstima, Globetronics, Opcom, Halex and Datasonic

2018-07-31 theedgemarkets
KUALA LUMPUR (July 31): Based on corporate announcements and news flow today, companies in focus on Wednesday (Aug 1) may include: Scomi Group Bhd, YTL Hospitality Real Estate Investment Trust (REIT), Serba Dinamik Holdings Bhd, Perusahaan Sadur Timah Malaysia Bhd, Globetronics Technology Bhd, Opcom Holdings Bhd, Halex Holdings Bhd and Datasonic Group Bhd.
SLLXF 5436 5216 4863 0035 5109 7158 HIL MYTEF 5151 7022 GBTKF

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...